deferiprone has been researched along with Arthropathies in 15 studies
Deferiprone: A pyridone derivative and iron chelator that is used in the treatment of IRON OVERLOAD in patients with THALASSEMIA.
deferiprone : A member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study was undertaken to describe the radiographic and MRI appearances of arthropathy of the knees in 14 patients with beta-thalassemia major undergoing chelation therapy with deferiprone (L1)." | 7.72 | Radiographic and MRI features of deferiprone-related arthropathy of the knees in patients with beta-thalassemia. ( Babyn, PS; Di Gennaro, L; Eber, SW; Kellenberger, CJ; Saurenmann, T; Schmugge, M; Willi, UV, 2004) |
| "This study was undertaken to describe the radiographic and MRI appearances of arthropathy of the knees in 14 patients with beta-thalassemia major undergoing chelation therapy with deferiprone (L1)." | 3.72 | Radiographic and MRI features of deferiprone-related arthropathy of the knees in patients with beta-thalassemia. ( Babyn, PS; Di Gennaro, L; Eber, SW; Kellenberger, CJ; Saurenmann, T; Schmugge, M; Willi, UV, 2004) |
| "In previous trials, the orally active iron chelator deferiprone (L1) has been associated with sporadic agranulocytosis, milder forms of neutropenia and other side-effects." | 3.70 | Safety profile of the oral iron chelator deferiprone: a multicentre study. ( Cohen, AR; Dipalma, A; Galanello, R; Piga, A; Tricta, F; Vullo, C, 2000) |
| "The rates of agranulocytosis (absolute neutrophil count [ANC] < 500 x 10(9)/L) and milder forms of neutropenia (ANC, 500-1500 x 10(9)/L) were 0." | 2.71 | Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. ( Cohen, AR; De Sanctis, V; Galanello, R; Piga, A; Tricta, F, 2003) |
| "Thrombocytopenia is one of the major side effects in young thalassaemics and necessitates frequent close monitoring of blood counts but its resolution after discontinuation and absence of clinical evidence of bleeding does not preclude its use." | 2.71 | Safety of oral iron chelator deferiprone in young thalassaemics. ( Chandra, J; Naithani, R; Sharma, S, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (40.00) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 2 (13.33) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Dhawan, P | 1 |
| Kanojia, RK | 1 |
| Chandra, J | 2 |
| Kumar, A | 1 |
| Anand, R | 1 |
| Gupta, S | 1 |
| Noureldine, MHA | 1 |
| Taher, AT | 1 |
| Haydar, AA | 1 |
| Berjawi, A | 1 |
| Khamashta, MA | 1 |
| Uthman, I | 1 |
| Totadri, S | 1 |
| Bansal, D | 1 |
| Bhatia, P | 1 |
| Attri, SV | 1 |
| Trehan, A | 1 |
| Marwaha, RK | 1 |
| Cohen, AR | 2 |
| Galanello, R | 2 |
| Piga, A | 3 |
| De Sanctis, V | 1 |
| Tricta, F | 2 |
| Kellenberger, CJ | 1 |
| Schmugge, M | 1 |
| Saurenmann, T | 1 |
| Di Gennaro, L | 1 |
| Eber, SW | 1 |
| Willi, UV | 1 |
| Babyn, PS | 1 |
| Naithani, R | 1 |
| Sharma, S | 1 |
| Roggero, S | 1 |
| Vinciguerra, T | 1 |
| Sacchetti, L | 1 |
| Gallo, V | 1 |
| Longo, F | 1 |
| Mudiyanse, RM | 1 |
| Hoffbrand, AV | 3 |
| Wonke, B | 2 |
| Adhikari, D | 1 |
| al-Refaie, FN | 1 |
| Olivieri, NF | 1 |
| Matsui, D | 1 |
| Liu, PP | 1 |
| Blendis, L | 1 |
| Cameron, R | 1 |
| McClelland, RA | 1 |
| Templeton, DM | 1 |
| Koren, G | 1 |
| Dipalma, A | 1 |
| Vullo, C | 1 |
| Berdoukas, V | 1 |
3 reviews available for deferiprone and Arthropathies
| Article | Year |
|---|---|
Rheumatological complications of beta-thalassaemia: an overview.
Topics: Arthritis; beta-Thalassemia; Blood Transfusion; Connective Tissue Diseases; Deferiprone; Femur Head | 2018 |
Deferiprone: New insight.
Topics: Agranulocytosis; Cardiomyopathies; Clinical Trials as Topic; Deferiprone; Deferoxamine; Follow-Up St | 2005 |
Oral iron chelation.
Topics: Administration, Oral; Agranulocytosis; Clinical Trials as Topic; Deferiprone; Humans; Iron Chelating | 1996 |
3 trials available for deferiprone and Arthropathies
| Article | Year |
|---|---|
Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone.
Topics: Administration, Oral; Adolescent; Adult; Agranulocytosis; Alanine Transaminase; beta-Thalassemia; Ch | 2003 |
Safety of oral iron chelator deferiprone in young thalassaemics.
Topics: Blood Cell Count; Child; Child, Preschool; Deferiprone; Female; Follow-Up Studies; Humans; Iron Chel | 2005 |
Oral iron chelation with 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron loaded thalassemia patients.
Topics: Administration, Oral; beta-Thalassemia; Chelation Therapy; Deferiprone; Humans; Iron; Iron Chelating | 1993 |
9 other studies available for deferiprone and Arthropathies
| Article | Year |
|---|---|
Wrist Joint Skeletal Changes in Children With Transfusion-dependent Thalassemia.
Topics: Adolescent; beta-Thalassemia; Blood Transfusion; Chelation Therapy; Child; Child, Preschool; Deferip | 2020 |
The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
Topics: Adolescent; Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Chemical and Drug Induced Liver I | 2015 |
Radiographic and MRI features of deferiprone-related arthropathy of the knees in patients with beta-thalassemia.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Deferiprone; Female; Humans; Iron Chelating Agents; Join | 2004 |
Thalassemia treatment and prevention in Uva Province, Sri Lanka: a public opinion survey.
Topics: Abortion, Eugenic; Adolescent; Adult; Blood Transfusion; Chelation Therapy; Combined Modality Therap | 2006 |
Deferiprone in iron overload.
Topics: Agranulocytosis; Clinical Trials, Phase I as Topic; Deferiprone; Humans; Iron Chelating Agents; Join | 1995 |
Deferiprone in iron overload.
Topics: Deferiprone; Gastrointestinal Diseases; Humans; Iron Chelating Agents; Joint Diseases; Neutropenia; | 1995 |
Arthropathy in thalassaemia patients receiving deferiprone.
Topics: Deferiprone; Humans; Iron Chelating Agents; Joint Diseases; Pyridones; Thalassemia | 1994 |
Safety profile of the oral iron chelator deferiprone: a multicentre study.
Topics: Agranulocytosis; Alanine Transaminase; beta-Thalassemia; Deferiprone; Gastrointestinal Diseases; Hum | 2000 |
Antinuclear antibodies in patients taking L1.
Topics: Antibodies, Antinuclear; Deferiprone; Humans; Joint Diseases; Pyridones | 1991 |